Predicting the Safety & Efficacy of Mouse Models

Time: 11:00 am
day: Day One


• Clarifying the differences between surrogate antibodies and your clinical candidate
• PKPD: understanding it’s importance and relevance in IO treatment
• Establishing how to determine dosing frequency and volume from your mouse models
• Measuring efficacy: determining mechanistic measures including surrogate endpoints in efficacy studies